Seino S., and Miki T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog Biophys Mol Biol 81 (2003) 133-176
Aguilar-Bryan L., and Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocrine Rev 20 (1999) 101-135
Aguilar-Bryan L., Clement IV J.P., Gonzalez G., Kunjilwar K., Babenko A., and Bryan J. Toward understanding the assembly and structure of KATP channels. Physiol Rev 78 (1998) 227-245
Aschcroft F.M., and Gribble F.M. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia 42 (1999) 903-919
Brayden J.E. Functional roles of KATP channels in vascular smooth muscle. Clin Exp Pharmacol Physiol 29 (2002) 312-316
Quayle J.M., Nelson M.T., and Standen N.B. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 77 (1997) 1165-1232
Hansen J.B. Towards selective KIR 6.2/SUR 1 potassium channel openers, medicinal chemistry and therapeutic perspectives. Curr Med Chem 13 (2006) 361-376
Mannhold R. KATP channel openers: structure-activity relationships and therapeutic potential. Med Res Rev 24 (2004) 213-266
Mannhold R. Structure-activity relationships of KATP channel openers. Curr Top Med Chem 6 (2006) 1031-1047
Robertson D.W., and Steinberg M.I. Potassium channel modulators: scientific applications and therapeutic promise. J Med Chem 33 (1990) 1529-1541
Wickenden A.D. K+ channels as therapeutic drug targets. Pharmacol Ther 94 (2002) 157-182
Pirotte B., de Tullio P., Antoine M.-H., Sebille S., Florence X., and Lebrun P. New insights in the development of ATP-sensitive potassium channel openers. Exp Opin Ther Pat 15 (2005) 497-504
Pirotte B., Fontaine J., and Lebrun P. Recent advances in the chemistry of potassium channel openers. Curr Med Chem 2 (1995) 573-582
de Tullio P., Becker B., Boverie S., Dabrowski M., Wahl P., Antoine M.-H., et al. Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1.1-dioxides. J Med Chem. 46 (2003) 3342-3353
de Tullio P., Pirotte B., Lebrun P., Fontaine J., Dupont L., Antoine M.-H., et al. 3- and 4-substituted 4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as potassium channel openers: synthesis, pharmacological evaluation, and structure-activity relationships. J Med Chem 39 (1996) 937-948
Lebrun P., Arkhammar P., Antoine M.-H., Nguyen Q.-A., Bondo-Hansen J., and Pirotte B. A potent diazoxide analogue activating ATP-sensitive K+ channels and inhibiting insulin release. Diabetologia 43 (2000) 723-732
Pirotte B., de Tullio P., Lebrun P., Antoine M.-H., Fontaine J., Masereel B., et al. 3-(Alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1.1-dioxides as powerful inhibitors of insulin release from rat pancreatic B-cells: A new class of potassium channel openers?. J Med Chem 36 (1993) 3211-3213
Pirotte B., Ouedraogo R., de Tullio P., Khelili S., Somers F., Boverie S., et al. 3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis and pharmacological evaluation. J Med Chem 43 (2000) 1456-1466
Antoine M.-H., Berkenboom G., Fang Z.Y., Fontaine J., Herchuelz A., and Lebrun P. Mechanical and ionic response of rat aorta to diazoxide. Eur J Pharmacol 216 (1992) 299-306
Lebrun P., Fang Z.Y., Antoine M.-H., Herchuelz A., Hermann M., Berkenboom G., et al. Hypoglycemic sulfonylureas antagonize the effects of cromakalim and pinacidil on 86Rb fluxes and contractile activity in the rat aorta. Pharmacology 41 (1990) 36-48
Becker B., Antoine M.-H., Nguyen Q.-A., Rigo B., Cosgrove K.E., Barnes P.D., et al. Synthesis and characterization of a quinolinonic compound activating ATP-sensitive K+ channels in endocrine and smooth muscle tissues. Br J Pharmacol 134 (2001) 375-385
Ghisdal P., Gomez J.P., and Morel N. Action of a NO donor on the excitation-contraction pathway activated by noradrenaline in rat superior mesenteric artery. J Physiol 522 (2000) 83-96
Aschcroft F.M., and Rorsman P. Electrophysiology of the pancreatic β-cell. Prog Biophys Mol Biol 54 (1989) 87-143
Malaisse W.J., and Lebrun P. Mechanisms of sulfonylurea-induced insulin release. Diab Care 13 Suppl. 3 (1990) 9-17
Quast U., and Cook N.S. In vitro and in vivo comparison of two K+ channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide. J Pharmacol Exp Ther 250 (1989) 261-271
Antoine M.-H., Pirotte B., Hermann M., de Tullio P., Delarge J., Herchuelz A., et al. Cationic and secretory effects of BPDZ 44 and diazoxide in rat pancreatic islets. Experientia 50 (1994) 830-832
Cosgrove K.E., Antoine M.-H., Lee A.T., Barnes P.D., de Tullio P., Clayton P., et al. BPDZ154 activates adenosine 5'-triphosphate-sensitive potassium channels: In vitro studies using rodent insulin-secreting cells and islets isolated from patients with hyperinsulinism. J Clin Endocrinol Metab 87 (2002) 4860-4868
Dabrowski M., Ashcroft F.M., Ashfield R., Lebrun P., Pirotte B., Egebjerg J., et al. The novel diazoxide analog 3-isopropylamino-7-methoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide is a selective KIR6.2/SUR1 channel opener. Diabetes 51 (2002) 1896-1906
de Tullio P., Boverie S., Becker B., Antoine M.-H., Nguyen Q.-A., Francotte P., et al. 3-alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel openers: effect of 6.7-disubstitution on potency and tissue selectivity. J Med Chem 48 (2005) 4990-5000
Lebrun P., Antoine M.-H., Ouedraogo R., Kane C., Dunne M., Hermann M., et al. Activation of ATP-dependent K+ channels and inhibition of insulin release: effect of BPDZ 62. J. Pharmacol Exp Ther 277 (1996) 156-162
Pirotte B., Antoine M.-H., de Tullio P., Hermann M., Herchuelz A., Delarge J., et al. A pyridothiadiazine (BPDZ 44) as a new and potent activator of ATP-sensitive K+ channels. Biochem Pharmacol 47 (1994) 1381-1386
de Tullio P., Lebrun P., Florence X., Antoine M.H., Francotte P., and Pirotte B. Selective pancreatic ATP-sensitive potassium channel openers for the treatment of glucose homeostasis disorders. Drugs Fut 31 (2006) 991-1001
Nielsen F.E., Bodvarsdottir T.B., Worsaae A., McKay P., and Stidsen C.E. Boonen HCM et al.6-chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1.1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic β-cells. J Med Chem 45 (2002) 4171-4187
Nielsen F.E., Ebdrup S., Frost Jensen A., Ynddal L., Bodvarsdottir T.B., Stidsen C., et al. New 3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1.1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells. J Med Chem 49 (2006) 4127-4139
Kurumbail R.G., Stevens A.M., Gierse J.K., McDonald J.J., Stegeman R.A., Pak J.Y., et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384 (1996) 644-648
Quast U., and Baumlin Y. Comparison of the effluxes of 42K+ and 86Rb+ elicited by cromakalim (BRL 34915) in tonic and phasic vascular tissue. Naunyn Schmiedeberg's Arch Pharmacol 338 (1998) 319-326
Edwards G., and Weston A.H. The pharmacology of ATP-sensitive potassium channels. Ann Rev Pharmacol Toxicol 33 (1993) 597-637
